Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Feb;28(2):77–86. doi: 10.1007/BF00199106

Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies

Shuen-Kuei Liao 1,✉, Connie Meranda 1, Barry P Avner 1, Tammy Romano 1, Salah Husseini 1, Bobby Kimbro 1, Robert K Oldham 1
PMCID: PMC11037965  PMID: 2645052

Abstract

A panel of 14 monoclonal antibodies (MoAbs) (4 raised against breast cancer, 6 against colon cancer and 4 against melanoma) were used to phenotype frozen sections of tumor biopsies obtained from 110 patients, by avidin-biotin-peroxidase complex techniques. We observed heterogeneity of antigen expression among the multiple metastatic lesions of single patients, as well as among tumor lesions from different patients with similar tumor histotypes. A wide range of cross-reactivity of anti-(breast-carcinoma) and anti-(colon-carcinoma) MoAbs with other carcinoma histotypes and limited reactivity with melanoma and sarcoma was detected. Some of our anti-melanoma MoAbs were also found to cross-react with selected carcinomas. Nine of the 14 MoAbs most reactive with carcinomas of diverse histotypes have been identified. A mixture or ‘cocktail’ of different MoAbs could be selected for each individual patient in order to achieve binding of MoAbs with most, if not 100% of tumor cells. This study illustrates the approach that we have taken to individualize the cocktail of MoAbs for the development of patient-specific therapeutic immunoconjugates.

Keywords: Breast Cancer, Carcinoma, Melanoma, Colon Cancer, Sarcoma

References

  • 1.Albino HP, Lloyd KO, Houghton AN, Oettgen HF, Old LJ. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. J Exp Med. 1981;154:1764–1778. doi: 10.1084/jem.154.6.1764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Armitage NC, Perkins AC, Pimm MV, Wastic ML, Baldwin RW, Hardcastle JD. Imaging of primary and metastatic colorectal cancer using an 111In-labeled anti-tumor monoclonal antibody (79IT/36) Nucl Med Commun. 1985;6:623–631. doi: 10.1097/00006231-198510000-00003. [DOI] [PubMed] [Google Scholar]
  • 3.Ashall F, Bramwell ME, Harris H. A new marker for human cancer cells. The Ca antigen and the CA1 antibody. Lancet. 1982;2:1–6. doi: 10.1016/s0140-6736(82)91150-3. [DOI] [PubMed] [Google Scholar]
  • 4.Aukerman SL, Fidler IJ. The heterogeneous nature of metastatic neoplasms: relevance to biotherapy. In: Oldham RK, editor. Principles of cancer biotherapy. New York: Raven Press; 1987. pp. 21–47. [Google Scholar]
  • 5.Avner BP, Liao S-K, Avner B, DeCell K, Oldham RK (1988) Therapeutic murine monoclonal antibodies developed for individual cancer patients. J Biol Response Mod (in press) [PubMed]
  • 6.Ballou B, Jeffe R, Taylor RJ, Solter D, Hakala TR. Tumor radioimmunolocation: differential antibody retention by antigenic normal tissue and tumor. J Immunol. 1984;132:2111–2116. [PubMed] [Google Scholar]
  • 7.Broers JLV, Rot MK, Oostendrop T, Huysmans A, Wagenaar SS, Wiersma-van Tilburg AJM, Vooigs GP, Ramacker FCS. Immunocytochemical detection of human lung cancer heterogeneity using antibodies to epithelial, neuronal and neuroendocrine antigens. Cancer Res. 1978;47:3225–3234. [PubMed] [Google Scholar]
  • 8.Carrasquillo JA, Abrams PG, Schroff RW, Keenan AM, Morgan AC, Foon KA, Reynolds JC, Perinthesis P, Horowitz M, Larson SM. Improved imaging of metastatic melanoma with high dose 9.2.27 In-111 monoclonal antibody. J Nucl Med. 1985;26(5):67. [Google Scholar]
  • 9.Ceriani RL, Blank EW. An experimental model for the immunological treatment of breast cancer. In: Ceriani RL, editor. Monoclonal antibodies and breast cancer. Boston: Martinus Nijhoff Publishers; 1985. pp. 248–266. [Google Scholar]
  • 10.Chatel J-F, Saccavini J-C, Fumoleau P, Douillard J-Y, Curtet C, Kremer M, LeMevel B, Koprowski H. Immunoscintigraphy of colon carcinoma. J Nucl Med. 1984;25:307–314. [PubMed] [Google Scholar]
  • 11.Edwards PAW. Heterogeneous expression of cell surface antigens in normal epithelia and their tumors, revealed by monoclonal antibodies. Br J Cancer. 1985;51:149–160. doi: 10.1038/bjc.1985.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Epenetos AA, Mather S, Granowska M, Britton KE, Taylor-Papadimittiou J, Nimmon CC, Shepherd J, Duobin H, Hawkins LR, Malpas JS, Bodmer WF. Targeting of iodine-125 labeled tumor-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumors. Lancet. 1982;2:999–1004. doi: 10.1016/s0140-6736(82)90046-0. [DOI] [PubMed] [Google Scholar]
  • 13.Fargion S, Carney D, Mulshine J, Rosen S, Bunn P, Jewett P, Cuttitta F, Gazdar A, Minna J. Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res. 1986;46:2633–2638. [PubMed] [Google Scholar]
  • 14.Heppner GH, Miller BE. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev. 1983;2:5–23. doi: 10.1007/BF00046903. [DOI] [PubMed] [Google Scholar]
  • 15.Horan Hand P, Colcher D, Wunderlich D, Nuti M, Teramoto YA, Kufe D, Schlom J. Rational basis of the diagnostic, prognostic, and therapeutic utility of monoclonal antibodies in the management of human breast cancer. In: Chabner BA, editor. Rational basis for chemotherapy. New York: Alan R Liss; 1983. pp. 315–358. [Google Scholar]
  • 16.Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA. 1985;82:1242–1246. doi: 10.1073/pnas.82.4.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Jungermar JA, Kin-Hung PY, Zanelli CI. Radiation absorbed dose estimates at the cellular level for some electronemitting radionuclides for radioimmunotherapy. Int J Appl Radiat Isotopes. 1984;35:883–888. doi: 10.1016/0020-708x(84)90025-5. [DOI] [PubMed] [Google Scholar]
  • 18.Krizan Z, Murray JL, Hersh EM, Rosenblum MG, Glenn HJ, Gschwind CR, Carlo DJ. Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants. Cancer Res. 1985;45:4904–4909. [PubMed] [Google Scholar]
  • 19.Larson SM, Brown JP, Wright PW, Carrasquillo JA, Hellstrom I, Hellstrom KE. Imaging of melanoma with I-131-labeled monoclonal antibodies. J Nucl Med. 1983;24:123–129. [PubMed] [Google Scholar]
  • 20.Leong SPL, Bolen JL, Chee DO, Smith VR, Taylor JC, Benfield JR, Klevecz RR. Cell-cycle-dependent expression of human melanoma membrane antigen analyzed by flow cytometry. Cancer. 1985;55:1276–1283. doi: 10.1002/1097-0142(19850315)55:6<1276::aid-cncr2820550621>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  • 21.Levy R, Miller RA. Biological and clinical indications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Annu Rev Med. 1983;34:107–116. doi: 10.1146/annurev.me.34.020183.000543. [DOI] [PubMed] [Google Scholar]
  • 22.Liao S-K, Clarke JB, Khosravi M, Kwong PE, Brickenden A, Dent PB. Human melanoma-specific oncofetal antigen defined by a mouse monoclonal antibody. Int J Cancer. 1982;30:573–580. doi: 10.1002/ijc.2910300507. [DOI] [PubMed] [Google Scholar]
  • 23.Liao S-K, Kwong PC, Clarke BJ, Dent PB, Ryan ED, Khosravi MJ, Leferte S, Krantz MJ. Monoclonal antibody recognizing human melanoma-carcinoma cross-reacting oncofetal antigen epitopically associated with carcinoembryonic antigen. J Natl Cancer Inst. 1985;74:1047–1058. [PubMed] [Google Scholar]
  • 24.Liao S-K, Avner BP, Meranda C, Kanamaru T. Monoclonal antibody BTMA8 with apparent selective specificity for adenocarcinomas of breast, colorectum, and pancreas. Proc Am Assoc Cancer Res. 1987;28:362. [Google Scholar]
  • 25.Liao S-K, Khosravi MJ, Brown JP, Kwong PC. Difference in cell binding patterns of two monoclonal antibodies recognizing distinct epitopes on a human melanoma associated antigen. Mol Immunol. 1987;24:1–9. doi: 10.1016/0161-5890(87)90105-2. [DOI] [PubMed] [Google Scholar]
  • 26.Lindmo T, Davies C, Rofstad EK, Rofstad O, Sundan A. Antigen expression in human melanoma cells in relation to growth conditions and cell cycle distribution. Int J Cancer. 1984;33:167–171. doi: 10.1002/ijc.2910330203. [DOI] [PubMed] [Google Scholar]
  • 27.Lowder JN, Meeker TC, Campbell M, Garcia CF, Gralow J, Miller RA, Warnde R, Levy R. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood. 1987;69:199–210. [PubMed] [Google Scholar]
  • 28.Mach J-P, Buchegger F, Forni M, Ritschard J, Berche C, Lumbroso JD, Schnayer M, Ginardet C, Accolla RS, Carrel S. Use of radiolabeled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today. 1981;2:239–249. doi: 10.1016/0167-5699(81)90011-6. [DOI] [PubMed] [Google Scholar]
  • 29.McGee J, Woods JC, Ashall F, Bramwell ME, Harris H. A new marker for human cancer cells. 2. Immunohistochemical detection of the Ca antigen in human tissues with the Cal antibody. Lancet. 1982;2:7–10. doi: 10.1016/s0140-6736(82)91151-5. [DOI] [PubMed] [Google Scholar]
  • 30.Natali PG, Bigotti A, Cavaliere R, Liao S-K, Taniguchi M, Matsui M, Ferrone S. Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. Cancer Res. 1985;45:2883–2889. [PubMed] [Google Scholar]
  • 31.Natali PG, Roberts JT, Defilippo F, Bigotti A, Dent PB, Ferrone S, Liao S-K. Immunohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significance. Cancer. 1987;59:55–63. doi: 10.1002/1097-0142(19870101)59:1<55::aid-cncr2820590115>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  • 32.Ogden JR, Leung K. Letter to Editors: purification of murine antibodies by caprylic acid. J Immunol Methods. 1988;111:283–184. doi: 10.1016/0022-1759(88)90139-1. [DOI] [PubMed] [Google Scholar]
  • 33.Oldham RK. Monoclonal antibodies and immunoconjugates as anti-cancer agents. In: Szentivanyi A, Mauren P, editors. Antibodies — structure, synthesis, function and immunologic intervention in disease. New York: Plenum Press; 1987. pp. 189–200. [Google Scholar]
  • 34.Oldham RK, Foon KA, Morgan AC, Woodhouse CS, Schroff RW, Abrams PG, Fer M, Schoenberger CS, Farrell M, Kimball E. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol. 1984;11:1235–1244. doi: 10.1200/JCO.1984.2.11.1235. [DOI] [PubMed] [Google Scholar]
  • 35.Oldham RK, Lewis M, Orr DW, Avner BP, Liao S-K, Ogden JR, Avner B, Birch R. (1988) Adriamycin custom tailored immunoconjugates in the treatment of human malignancies. Mol Biother (in press) [PubMed]
  • 36.Olsson L, Sorenson HR, Behnke O. Intratumoral phenotypic diversity of clonal human lung tumor cell lines and consequences for analysis with monoclonal antibodies. Cancer. 1984;54:1757–1765. doi: 10.1002/1097-0142(19841101)54:9<1757::aid-cncr2820540902>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  • 37.Pallesen G, Jepsen FL, Hastrup J, Ipsen A, Huidberg N. Experience with the Oxford tumor marker (Cal) in serous fluids. Lancet. 1983;i:1326. doi: 10.1016/s0140-6736(83)92430-3. [DOI] [PubMed] [Google Scholar]
  • 38.Rainsbury RM. The localization of human breast carcinomas by radiolabeled monoclonal antibodies. Br J Surg. 1984;71:805–812. doi: 10.1002/bjs.1800711023. [DOI] [PubMed] [Google Scholar]
  • 39.Ritz J, Pesando JM, Notis-McConarty J, Schlossman SF. Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro. J Immunol. 1980;125:1506–1514. [PubMed] [Google Scholar]
  • 40.Rowland GF, Axton CA, Baldwin RW, Brown JP, Corvalan JRF, Embleton MJ, Gore VA, Hellstrom I, Hellstrom KE, Jacobs E, Marsden CH, Pimm MV, Simmonds RG, Smith W. Anti-tumor properties of vindesine-monoclonal antibody conjugates. Cancer Immunol Immunother. 1986;19:1–7. doi: 10.1007/BF00199304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ruiter DJ, Fleuren GJ, Warnaar SO, editors. Application of monoclonal antibodies in tumor pathology. Dordrecht/Boston/Lancaster: Martinus Nijhoff Publishers; 1987. [Google Scholar]
  • 42.Russo C, Callegaro L, Lanza E, Ferrone S. Purification of IgG monoclonal antibodies by caprylic acid precipitation. J Immunol Methods. 1983;65:269–270. doi: 10.1016/0022-1759(83)90324-1. [DOI] [PubMed] [Google Scholar]
  • 43.Schroff RW, Farrell MM, Klein RA, Oldham RK, Foon KA. T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. J Immunol. 1984;133:1641–1648. [PubMed] [Google Scholar]
  • 44.Schroff RW, Morgan AC, Woodhouse CS, Abrams PG, Farrell MM, Carpenter BE, Oldham RK, Foon KA. Monoclonal antibody therapy in malignant melanoma: factors effecting in vivo localization. J Biol Response Mod. 1987;6:457–472. [PubMed] [Google Scholar]
  • 45.Shawler DL, Miceli MC, Wormsley SB, Royston I, Dillman RO. Induction of in vitro and in vivo antigeneic modulation by the anti-human T-cell monoclonal antibody T 101. Cancer Res. 1984;44:5921–5927. [PubMed] [Google Scholar]
  • 46.Spitler LE, del Rio M, Kentigan A, Wedel NI, Brophy NA, Miller IL, Harkonen WS, Rosendorf LL, Shannon CE, Lee HM, Mischak RP, Kawahata RT, Stoudemine JB, Fradkin LB, Bautista EE, Dellio CL, Mendell SC, Scannon PJ. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res. 1987;47:1717–1723. [PubMed] [Google Scholar]
  • 47.Taupier MA, Kearney JK, Leibson PJ, Loken MR, Schreiber H. Nonrandom escape of tumor cells from immune lysis due to intraclonal fluctuations in antigen expression. Cancer Res. 1983;43:4050–4056. [PubMed] [Google Scholar]
  • 48.Woodruff MFA. Cellular heterogeneity in tumors. Br J Cancer. 1983;47:589–594. doi: 10.1038/bjc.1983.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Yeh M-Y, Hellstrom I, Hellstrom KE. Clonal variation in expression of a human melanoma antigen defined by a monoclonal antibody. J Immunol. 1981;126:1312–1317. [PubMed] [Google Scholar]
  • 50.Ziai MR, Imberti L, Nicostra MR, Badaracco G, Segatto O, Natali P, Ferrone S. Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen. Cancer Res. 1987;24:2474–2480. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES